Skip to main content
. 2020 Dec 16;10:22088. doi: 10.1038/s41598-020-79181-6

Table 2.

Clinicopathological characteristics of pancreatic cancer patients selected for MUC4 staining.

Variable PDAC + OJ (n = 25) PDAC (n = 25) NE (n = 11) NORMAL (n = 4)
n (%) n (%) n (%) n (%)
Gender
Male 13 (52.0) 17 (68.0) 8 (72.7) 1 (25.0)
Female 12 (48.0) 8 (32.0) 3 (27.3) 3 (75.0)
Age
˂ 65 6 (24.0) 10 (40.0) 4 (36.36) 4 (100.0)
 ≥ 65 19 (76.0) 15 (60.0) 7 (63.64) 0 (0.0)
Location of primary tumor
Papilla of Vater 3 (12.0) 0 (0.0) 0 (0.0)
Head 22 (88.0) 18 (72.0) 6 (54.54)
Head/Body 0 (0.0) 5 (20.0) 0 (0.0)
Body 0 (0.0) 1 (4.0) 1 (9.1)
Tail 0 (0.0) 1 (4.0) 4 (36.36)
Hystological type
Well differentiated 3 (12.0) 3 (12.0) 4 (36.37)
Moderately differentiated 12 (48.0) 18 (72.0) 7 (63.63)
Poorly differentiated 10 (40.0) 4 (16.0) 0 (0.0)
Stage of the cancer
II 2 (8.0) 4 (16.0) 8 (72.73)
III 10 (40.0) 12 (48.0) 3 (27.27)
IV 13 (52.0) 9 36.0)
Lymphatic invasion
Negative 17 (68.0) 20 (80.0) 11 (100.0)
Positive 8 (32.0) 5 (20.0) 0 (0.0)
Metastasis
Lung 2 (8.0) 4 (16.0) 0 (0.0)
Liver 6 (24.0) 10 (40.0) 2 (18.18)
Colon 0 (0.0) 2 (8.0) 0 (0.0)
Gall bladder 1 (4.0) 0 (0.0) 0 (0.0)